PXY Stock Overview
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Provectus Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.045 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.04 |
| Beta | 0.47 |
| 1 Month Change | -7.22% |
| 3 Month Change | -29.69% |
| 1 Year Change | 13.92% |
| 3 Year Change | 2.27% |
| 5 Year Change | -16.67% |
| Change since IPO | -95.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| PXY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.8% |
| 1Y | 13.9% | -27.7% | 2.2% |
Return vs Industry: PXY exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: PXY exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| PXY volatility | |
|---|---|
| PXY Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PXY's share price has been volatile over the past 3 months.
Volatility Over Time: PXY's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 4 | n/a | www.provectusbio.com |
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.
Provectus Biopharmaceuticals, Inc. Fundamentals Summary
| PXY fundamental statistics | |
|---|---|
| Market cap | €55.61m |
| Earnings (TTM) | -€2.92m |
| Revenue (TTM) | €553.62k |
100.4x
P/S Ratio-19.1x
P/E RatioIs PXY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXY income statement (TTM) | |
|---|---|
| Revenue | US$601.44k |
| Cost of Revenue | US$2.31m |
| Gross Profit | -US$1.71m |
| Other Expenses | US$1.46m |
| Earnings | -US$3.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | -284.14% |
| Net Profit Margin | -527.24% |
| Debt/Equity Ratio | -40.8% |
How did PXY perform over the long term?
See historical performance and comparison